

Table 1: Summary of findings: PGIC (Much or very much improved).

Paroxetine

Milnacipran

Amitriptyline

Desvenlafaxine

Duloxetine

Esreboxetine

Total sample size ○ 1000 ○ 2000

Number of studies — 1 ■ 4 ■ 7 ■ 10

Treatment Class ■ N/A ■ SNRI ■ SSRI ■ TCA

**Outcome**

PGIC: much or very much improved

**Number of studies**

13

**Participants**

7258

**Number of conditions**

3

**Conditions (number of studies)**

Fibromyalgia (8); musculoskeletal (3); neuropathic (2)

**Number of interventions**

6

**Interventions (number of studies)**

Placebo (12); duloxetine (5); milnacipran (5); amitriptyline (1); desvenlafaxine (1); esreboxetine (1); paroxetine (1)

Intervention	Studies	Participants (placebo, intervention)	Relative effect (95% CI) <sup>†</sup>	Rank (95% CI) <sup>†</sup>	ROB <sup>2</sup>
Placebo	12	5434 (2717, 2717)		5 (4 to 7)	0.67
Duloxetine	5	1541 (773, 768)	2.2 (1.7 to 2.84)	2 (1 to 5)	0.40
Milnacipran	5	3809 (1543, 2266)	1.95 (1.61 to 2.35)	3 (1 to 5)	0.80
Amitriptyline	1	81 (0, 81)	0.71 (0 to 979662.23)	5 (1 to 7)	NA
Desvenlafaxine	1	659 (126, 533)	0.84 (0.54 to 1.29)	6 (4 to 7)	1.00
Esreboxetine	1	1086 (275, 811)	1.73 (1.18 to 2.54)	4 (1 to 5)	1.00
Paroxetine	1	82 (0, 82)	1.05 (0 to 1557320.89)	4 (1 to 7)	NA

<sup>†</sup> Direction of improvement: higher.
   
<sup>2</sup> Proportion of studies with at least one with high risk of bias (ROB) criterion.

Table 2: Summary of findings: PGIC (Any improvement).

Treatment Class: ● N/A ● NASSA ● SNRI ● TCA

Number of studies: — 1 — 2

Total sample size: ○ 50 ○ 100 ○ 150

**Outcome**  
PGIC: any improvement

**Number of studies**  
5

**Participants**  
550

**Number of conditions**  
2

**Conditions (number of studies)**  
Fibromyalgia (3); neuropathic (2)

**Number of interventions**  
6

**Interventions (number of studies)**  
Placebo (4); amitriptyline (2); carbamazepine (1); esreboxetine (1); milnacipran (1); mirtazapine (1); pregabalin (1)

**Design**  
Crossover (5); parallel (8)

Intervention	Studies	Participants (placebo, intervention)	Relative effect (95% CI) <sup>1</sup>	Rank (95% CI) <sup>1</sup>	ROB <sup>2</sup>
Placebo	4	370 (185, 185)		7 (4 to 7)	NA
Amitriptyline	2	74 (15, 59)	37.55 (1.64 to 1133.1)	2 (1 to 5)	NA
Carbamazepine	1	29 (15, 14)	9.96 (0.43 to 323.04)	4 (1 to 7)	NA
Esreboxetine	1	261 (132, 129)	2.22 (0.23 to 28.43)	5 (2 to 7)	NA
Milnacipran	1	125 (28, 97)	4.39 (0.46 to 34.29)	4 (1 to 7)	NA
Mirtazapine	1	32 (10, 22)	2.76 (0.24 to 31.09)	5 (1 to 7)	NA
Pregabalin	1	44 (0, 44)	43.33 (0.65 to 2334.48)	2 (1 to 6)	NA

<sup>1</sup> Direction of improvement: higher.

<sup>2</sup> Proportion of studies with at least one with high risk of bias (ROB) criterion.